The development of a quantitative and qualitative method based on UHPLC-QTOF MS/MS for evaluation paclitaxel-tetrandrine interaction and its application to a pharmacokinetic study.

[1]  G. Dranitsaris,et al.  Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[2]  D. Chiappetta,et al.  Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines. , 2016, Colloids and surfaces. B, Biointerfaces.

[3]  T. Tsai,et al.  Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats , 2016, Evidence-based complementary and alternative medicine : eCAM.

[4]  Kiyomi Ito,et al.  Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  M. Socinski,et al.  Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. , 2016, European journal of cancer.

[6]  Y. Ohe,et al.  Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer. , 2016, Clinical Therapeutics.

[7]  A. Pandey,et al.  Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. , 2015, Cancer cell.

[8]  Rongjun Chen,et al.  The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes , 2015, International journal of nanomedicine.

[9]  N. Agarwal,et al.  Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors , 2015, Investigational New Drugs.

[10]  H. Duff,et al.  Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis. , 2015, American journal of physiology. Heart and circulatory physiology.

[11]  Lanjuan Li,et al.  Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates , 2015, BMC Infectious Diseases.

[12]  Kunming Qin,et al.  Screening and identification of multiple constituents and their metabolites of Fangji Huangqi Tang in rats by ultra-high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry basing on coupling data processing techniques. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  Zhe-Sheng Chen,et al.  The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study , 2014, Oncotarget.

[14]  Joo-Youn Cho,et al.  Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. , 2014, British journal of clinical pharmacology.

[15]  M. Wink,et al.  Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[16]  P. Pan,et al.  Pathway-Dependent Inhibition of Paclitaxel Hydroxylation by Kinase Inhibitors and Assessment of Drug–Drug Interaction Potentials , 2014, Drug Metabolism and Disposition.

[17]  F. Priego-Capote,et al.  LC-MS/MS quantitative analysis of paclitaxel and its major metabolites in serum, plasma and tissue from women with ovarian cancer after intraperitoneal chemotherapy. , 2014, Journal of pharmaceutical and biomedical analysis.

[18]  C. Raston,et al.  Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles , 2014, Analytical and Bioanalytical Chemistry.

[19]  Hong Wang,et al.  Honokiol Enhances Paclitaxel Efficacy in Multi-Drug Resistant Human Cancer Model through the Induction of Apoptosis , 2014, PloS one.

[20]  Yong-He Zhang,et al.  Tetrandrine, an antihypertensive alkaloid, improves the sleep state of spontaneously hypertensive rats (SHRs). , 2014, Journal of ethnopharmacology.

[21]  J. Au,et al.  Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Cong Wang,et al.  Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line. , 2013, International journal of oncology.

[23]  Wei-Jia Kong,et al.  Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function. , 2013, Biological & pharmaceutical bulletin.

[24]  Jin Sun,et al.  A rapid and sensitive determination of paclitaxel in rat plasma by UPLC-MS/MS method: Application to a pharmacokinetic study , 2013 .

[25]  N. Mano,et al.  A rapid and sensitive LC/ESI-MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  Qiang Zhang,et al.  Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. , 2011, Biomaterials.

[27]  J. Schellens,et al.  A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  Gabriel S. Eichler,et al.  Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database , 2009, Molecular Cancer Therapeutics.

[29]  M. Cho,et al.  Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells , 2009, Journal of veterinary science.

[30]  O. Dolezal,et al.  Kinetic screening of antibody-Im7 conjugates by capture on a colicin E7 DNase domain using optical biosensors. , 2009, Analytical biochemistry.

[31]  Chunfu Wu,et al.  Effect of tetrandrine combined with epirubicin on the growth of human breast carcinoma multidrug resistance cell line. , 2008, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[32]  C. Hansch,et al.  Understanding tubulin/microtubule-taxane interactions: a quantitative structure-activity relationship study. , 2008, Molecular pharmaceutics.

[33]  Jia Wei,et al.  Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines , 2007, Cancer Chemotherapy and Pharmacology.

[34]  Helena Nordin,et al.  High-resolution characterization of antibody fragment/antigen interactions using Biacore T100. , 2006, Analytical biochemistry.

[35]  H. Gréen,et al.  Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface. , 2006, Rapid communications in mass spectrometry : RCM.

[36]  Jianping Zhou,et al.  Liquid chromatography/tandem triple-quadrupole mass spectrometry for determination of paclitaxel in rat tissues. , 2006, Rapid communications in mass spectrometry : RCM.

[37]  Jianping Zhou,et al.  Determination of paclitaxel in rat plasma by LC-MS-MS. , 2006, Journal of chromatographic science.

[38]  F. Gao,et al.  Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. , 2006, Leukemia research.

[39]  W. Fan,et al.  In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. , 2005, Anticancer research.

[40]  Jae-We Cho,et al.  Tetrandrine-induced apoptosis is mediated by activation of caspases and PKC-δ in U937 cells , 2004 .

[41]  Baoqing Guo,et al.  Cross-Resistance Studies of Isogenic Drug-Resistant Breast Tumor Cell Lines Support Recent Clinical Evidence Suggesting that Sensitivity to Paclitaxel may be Strongly Compromised by Prior Doxorubicin Exposure , 2004, Breast Cancer Research and Treatment.

[42]  L. Fu,et al.  Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance , 2004, Cancer Chemotherapy and Pharmacology.

[43]  J. Gallo,et al.  Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[44]  Chun-ching Lin,et al.  Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells. , 2003, Life sciences.

[45]  M. C. Quintana,et al.  Electrochemical study of taxol (paclitaxel) by cathodic stripping voltammetry: determination in human urine , 2003 .

[46]  F. Achike,et al.  Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. , 2002, Acta pharmacologica Sinica.

[47]  L. Fu,et al.  The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. , 2002, European journal of cancer.

[48]  L. Denis,et al.  Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  A. Mulchandani,et al.  Development of a fluorescence immunoassay for measurement of paclitaxel in human plasma. , 2000, Analytical biochemistry.

[50]  D. Fraier,et al.  Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection. , 1998, Journal of chromatography. A.

[51]  C. Bicamumpaka,et al.  Development of a fluorescence polarization immunoassay (FPIA) for the quantitative determination of paclitaxel. , 1998, Journal of immunological methods.

[52]  J. Beijnen,et al.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.

[53]  S. Suye,et al.  A receptor protein-based bioassay for quantitative determination of paclitaxel. , 1997, Analytical chemistry.

[54]  Yuan Jiang,et al.  A convenient tubulin-based quantitative assay for paclitaxel (Taxol) derivatives more effective in inducing assembly than the parent compound , 1996, Cancer Chemotherapy and Pharmacology.

[55]  D. Faulds,et al.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.